Enanta Pharmaceuticals (NASDAQ:ENTA) Upgraded to Buy at Jefferies Financial Group

Enanta Pharmaceuticals (NASDAQ:ENTA) was upgraded by equities research analysts at Jefferies Financial Group from a “hold” rating to a “buy” rating in a research note issued on Wednesday, Marketbeat reports. The brokerage presently has a $20.00 target price on the biotechnology company’s stock, up from their prior target price of $14.00. Jefferies Financial Group’s price objective points to a potential upside of 93.61% from the company’s current price.

A number of other research firms also recently issued reports on ENTA. JMP Securities increased their price target on shares of Enanta Pharmaceuticals from $24.00 to $25.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 12th. HC Wainwright began coverage on shares of Enanta Pharmaceuticals in a research note on Monday, July 28th. They issued a “buy” rating and a $20.00 price target for the company. Wall Street Zen upgraded shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, June 22nd. Evercore ISI cut their price objective on shares of Enanta Pharmaceuticals from $20.00 to $12.00 and set an “outperform” rating on the stock in a report on Monday, September 15th. Finally, Westpark Capital upped their price objective on shares of Enanta Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday. Six investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $20.83.

Enanta Pharmaceuticals Price Performance

ENTA stock opened at $10.33 on Wednesday. Enanta Pharmaceuticals has a 1 year low of $4.09 and a 1 year high of $15.34. The company has a market cap of $220.86 million, a P/E ratio of -2.39 and a beta of 0.89. The firm has a 50-day moving average of $8.31 and a 200 day moving average of $6.96.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.25) by $0.40. Enanta Pharmaceuticals had a negative net margin of 141.98% and a negative return on equity of 89.02%. The company had revenue of $18.31 million during the quarter, compared to the consensus estimate of $16.21 million. On average, equities research analysts expect that Enanta Pharmaceuticals will post -4.65 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. US Bancorp DE purchased a new stake in shares of Enanta Pharmaceuticals during the first quarter valued at approximately $36,000. GAMMA Investing LLC purchased a new stake in shares of Enanta Pharmaceuticals during the first quarter valued at approximately $40,000. Farther Finance Advisors LLC lifted its position in Enanta Pharmaceuticals by 11,558.0% during the second quarter. Farther Finance Advisors LLC now owns 5,829 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 5,779 shares during the period. Squarepoint Ops LLC bought a new position in Enanta Pharmaceuticals during the fourth quarter valued at approximately $66,000. Finally, MetLife Investment Management LLC bought a new position in Enanta Pharmaceuticals during the first quarter valued at approximately $72,000. Hedge funds and other institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.